The stock market ended Tuesday on a mixed note, with the S&P 500 and NASDAQ posting modest gains. Investor sentiment improved after President Donald Trump announced on Truth Social a proposed two-week ceasefire between the U.S.-Israel coalition and Iran.
Overall, S&P 500 and NASDAQ went up 0.1% to 6,617 and 22,018, respectively.
Chart of the Day
Here is the one-year chart of Eli Lilly (LLY) as of March 4, 2026, when the stock was at $1004.
Eli Lilly has gotten an enormous weight loss drug pipeline that is destined to drive growth for years to come. Recently, the U.S. Food and Drug Administration (FDA) approved Foundayo, Eli Lilly’s new weight-loss pill. It is a once-daily oral drug that has the same active ingredient (orforglipron) as the company’s Mounjaro and Zepbound.
Foundayo is gonna be a blockbuster, as many patients don’t want to take injections. In clinical trials, participants lost an average of 72 pounds after 72 weeks of treatment.
Meanwhile, Mounjaro and Zepbound continue to thrive, with last quarter’s sales rising 110% and 123%, respectively.
Looking ahead, the company expects to launch Orforglipron for chronic weight management in the U.S. by the second quarter of 2026, with broader international launches by 2027. And Retatrutude could be the biggest drug of all as it is a weight loss drug that has helped patients lose 80% of their liver fat. Retatrutude is expected to launch in 2028.
LLY is part of the Conservative Growth Portfolio, Growth Portfolio, and Focus List.
